An experimental model of colitis induced by dextran sulfate sodium from acute progresses to chronicity in C57BL/6: correlation between conditions of mice and the environment

Niloofar Taghipour1,2, Mahsa Molaei1, Nariman Mosaffa3, Mohammad Rostami-Nejad1, Hamid Asadzadeh Aghdaei2, Ali Anissian4, Pedram Azimzadeh2, Mohammad Reza Zali1
1Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Immunology Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Department of veterinary, College of Agriculture, Islamic Azad University, Abhar branch, Abhar, Iran

ABSTRACT

Aim: To induce acute colitis progresses to chronicity in C57BL/6 mice by dextran sulfate sodium.

Background: Murine models are essential tools to understand IBD pathogenesis. Among different types of chemically induced colitis models, the dextran sulfate sodium (DSS)-induced colitis model is the most common model of IBD, due to its simplicity.

Patients and methods: Male C57BL/6 mice 6–8 weeks old, were collected and matched by age with controls. C57BL/6 mice treated with 2 cycles of 3.5% DSS for 4 days and 4 days of pure water between each cycle. After that, mice were sacrificed and the entire colon was removed. Small sections of the colon were fixed in formaldehyde, embedded in paraffin and sectioned with a microtome. Sections were stained with hematoxylin eosin to analyses the degree of inflammation.

Results: After the first cycle oral administration of DSS, mice with severe and visible rectal bleeding and diarrhea entered into the acute phase. After day 4-5, bleeding and diarrhea were improved and mice entered into the chronic phase with peak levels of weight loss. Macroscopically, the inflammation was predominantly located in the distal colon. Microscopically, examination of the distal colon sections showed a decrease number of goblet cells, loss of crypts, signs of surface epithelial regeneration and moderate to severe infiltration of inflammatory cells in the mucosa.

Conclusion: In order to achieve an experimental colitis model, our protocol is recommended for future therapies in IBD experimental modeling.

Keywords: Inflammatory bowel disease, Murine models, DSS, C57BL/6.

Introduction

Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract that has often its onset in patients <30 years old (15-25 years) and has a chronic relapsing-remitting course (1-3). Despite many years of investigation, the etiopathogenesis of IBD has been remained unclear. According to the current hypothesis, the
complexity of a diverse genetic, environmental such as changed gut bacteria, as well as increased intestinal permeability play an important role in dysregulation of intestinal immunity and affect the small intestine and colon. Conventional medical management of IBD has focused on regulating the abnormal immune responses and excessive inflammation. For example, standard therapy includes sulfasalazine, 5-aminosalicylic acid, corticosteroids, immunosuppressive such as methotrexate, 6-mercaptopurine, azathioprine, and biological agents such as infliximab (4, 5). In the case of refractory disease or specific complications such as strictureplasty, permanent colostomy or ileostomy, bowel resection surgery is an optical option (6). Recently, Helminthic therapy has been used as a potential therapeutic strategy against refractory type or complicated condition compared to conventional treatment strategies (7, 8).

The absence of parasitic infection during the childhood is an important cause for the increased prevalence of IBD (7). Animal experimentation, as well as, clinical and epidemiological studies support this theory (9, 10).

A major advance in the study of inflammatory bowel disease that provides a strong support for the above concept has been the discovery and subsequent analysis of a number of models of mucosal inflammation that resemble IBD (11, 12). Several and variable animal models (especially mouse models) are also valuable tools to understand the pathogenesis of IBD. These models reflect the acute to chronic aspects of intestinal inflammation. IBD models fall into five main groups and each group provides opportunities to discover insights into the pathogenesis of IBD (13). These groups include: 1) Gene knockout (KO) models, including Trefoil factor-deficient mice, T cell receptor (TCR) mutant mice, Interleukin-2 KO/IL-2 receptor (R), a KO mice, IL-10 KO mice, and TNF-3’ un-translated region (UTR) KO mice. 2) Transgenic mouse models, including HLA B27 transgenic mice, IL-7 transgenic mice, Signal transducer and activating transcription (STAT)-4 transgenic mice. 3) Spontaneous colitis models including SAMP1/Yit mice, C3H/HejBir mice, cotton top tamarin. 4) Inducible models/kapten reagents, including Iodoacetamide-induced colitis, Acetic-acid-induced colitis, TNBS-induced colitis, DSS colitis, Oxazolone colitis and Peptidoglycan–polysaccharide (PG–PS) colitis. 5) adoptive transfer model including CD45RB transfer model, colitis induced by transfer of heat shock protein (hsp) 60-specific CD8 T cells.

Chemically induced mouse models of IBD are one of the most commonly used models because they are easy to induce, the onset, duration, and severity of inflammation are immediate and controllable (14,15).

The most common experimental colitis is induced by DSS. Simply changing the concentration of DSS administration can produce acute and chronic, or relapsing model. This model makes a high level of uniformity and reproducibility of most lesions in the distal colon (16, 17).

DSS colitis in mouse model revealed several features that are found in humans, including inflammation that starts in the distal colon and then involve the proximal colon (18). A dysplasia that resembles the clinical course of human UC, occurs frequently in the chronic phase of DSS colitis (19-20). Feeding mice with 1-5% DSS dissolved in water is a cause of weight loss, shortening the intestine, mucosal ulcers, and infiltration of inflammatory granulocytes.

It is believed that DSS causes a direct hyperosmotic damage to gut epithelial cells of the basal crypts and its effects on the inner mucus layer, allowing bacteria to penetrate to this layer. Acute colitis, which occurred after feeding with DSS, was considered to be induced by innate immunity.
In susceptible strains, the administration of DSS for several cycles (e.g., 7 days DSS, 14 days water) results in chronic colitis (15, 21). Differences in resolution of disease and progression to chronicity between the C57BL/6 and BALB/c mice most likely reflect the genetic ability to mount different inflammatory responses and/or healing mechanisms as observed by the different cytokine profiles (22). In this study, we used C57BL/6 mice to create an experimental model of colitis induced by dextran sulfate sodium and investigated the correlation between the conditions of mice and the environment.

**Materials and Methods**

**Mice**

Male C57BL/6 mice 6–8 wk old, weight 17–21 g, were purchased from the animal laboratory core facility of Royan Institute of Iran. The mice were matched by age with a control group. Before starting the experiment, to rule out any parasite infection in mice, stool samples were collected from each mouse and evaluated by formalin-ether concentration.

The mice were kept in animal house facilities at the Immunology department of Shahid Beheshti University of Medical Sciences with 12:12-h light-dark cycles in standard animal cages and fed with standard pellet diet, as well as plastic bottle water ad libitum. Mice were acclimatized to these conditions for 1 week before entering the study.

**Induction of colitis**

Commercial dextran sodium sulfate (DSS) (MW 36–50kDa, MP Biomedicals, OH, USA) dissolved in a drinking water with 3.5-5% concentration (w/v) to feed C57BL/6 mice. The control group (Untreated mice) received only water. Fresh DSS solutions were prepared daily.

As C57BL/6 mice exposed to 5% DSS (for 4 days) became too sick that often happened to their death before complete the study, a lower concentration (3.5%) was used.

For the chronic DSS-induced colitis, mice were received 2 cycles of DSS at 4 days/cycle and 4 days of pure drinking water between each cycle. In duration of adding DSS to drinking water, to control body weight, general health condition, stool consistency and fecal blood, mice monitored and data were recorded daily.

Clinical assessment of inflammation included:

(A) Body weight loss, negative: <1%, 1 plus:1–5%, 2 plus: 5–10%, 3 plus:10–15% and 4 plus:> 15% weight loss.

Percentage of weight loss was calculated by dividing body weight on the specified day in accordance with body weight on day 0 (baseline) (23). If each mouse had lost more than 25 percent of body weight, it was recommended to be killed by euthanasia as guidelines (24).

(B) Stool consistency /diarrhoea. negative : normal, 1 plus: Slightly loose feces , 2 plus: loose stools, 3 plus: watery diarrhea and (C) fecal blood, negative: no bleeding, 1 plus: slightly bloody (by occult blood kit), 2 plus : bloody, 3 plus : gross bleeding and blood in whole colon . To observe the status of disposal of blood, beds of cages were covered with white paper towels that were replaced every day.

**Histology**

At the end of the procedure, mice were sacrificed and the entire colon was rapidly removed and separated from the cecum, then cleared from feces and blood by flashing cold PBS. Small sections of the colon were fixed in 4-10% formaldehyde, embedded in paraffin and sectioned at 4-5µm thickness with a microtome. Sections were stained with hematoxylin & eosin to analyse the degree of inflammation blindly (25).

The pathophysiology of the tissue was characterized by the presence of epithelial damage, inflammatory cells infiltration, crypt loss, and reduction of goblet cells.
Results

DSS induced models of mucosal inflammation has been used over two decades in the IBD pathogenesis and preclinical studies (26). C57BL/6 is highly susceptible to DSS colitis, but is relatively resistant to TNBS induced colitis (27).

After the first cycle of oral administration of DSS (first 4d), animal entered into the acute phase of disease. Visible signs of disease, including reduced mobility, a hunched back, and raised fur were seen in mice. Peak levels of severe and visible bleeding (rectal bleeding), as well as diarrhea were found at day 4 (Figures 1, 2, and 3).

![Figure 1](image1.png)

**Figure 1.** Diarrhea score in C57BL/6 mice received DSS during 16 days study.

![Figure 2](image2.png)

**Figure 2.** Visible fecal blood scores in C57BL/6 +DSS mice during 16 days study.

After day 4-5, improvement of bleeding and diarrhea were seen and mice entered into the chronic phase. Weight loss was started from day 4 in C57BL/6 mice (Figure 4).

Body weights were increased a little during the first three days and began to decrease while the bleeding started.

Macroscopically, the inflammation was predominantly located in the distal colon. The length of the colon reduced as the disease developed and was significantly shorter at day 4 (18-22%).

![Figure 3](image3.png)

**Figure 3.** Visible bleeding and diarrhea were found on days 4-5.
Reduction in cecum size, as well as occasional blood in the small intestinal lumen, and stomach was observed on day 4. Furthermore, thickening of the colon wall in DSS colitis was observed (Figure 5).

Oral administration of DSS in 2 cycles was induced chronic colitis in C57BL/6. Chronic colitis was characterized by a noticeable decrease in colon length, bleeding, and ulceration in mouse models, and grossly thickened walls.

**Pathological analysis**

Microscopic examination of the distal colon sections stained by hematoxylin and eosin showed a marked inflammation in C57BL/6 mice treated with 2 cycles of DSS in 4 days/cycle during 16 days study.

C57BL/6 +DSS mice showed small changes in the surface of the epithelium, although a visible infiltration of inflammatory cells to the mucosa was seen.

The histological changes were clearly shown by a decreased number of goblet cells and loss of crypts, signs of surface epithelial regeneration, as well as moderate to severe infiltration of inflammatory cells to the mucosa (Figure 6).

**Discussion**

Different mouse models have been greatly used to understand the pathophysiology and developing therapeutic strategies for IBD (28). DSS induced colitis model is very popular in IBD research due to its simplicity, reproducibility, rapidity and controllability. The DSS-induced colitis model gives very important information regarding the interactions between gut immunity, microbiota, host genetics, diet and other environmental factors in maintaining gastrointestinal homeostasis (24).

In this study, we described a new approach to induce progressive chronic colitis in C57BL/6 mice. We also showed different phases of colitis development, which classified as acute, chronic,
and recovery phases. This classification is based on the clinical symptoms and histopathological changes.

DSS is often administered in a dose range of 1–5% for 7-14 days to induce an acute IBD in C57BL/6 mice (21, 29). To induce chronic phase of IBD, DSS is administered in three to five cycles with a 1-2 week rest period between cycles (15). Our results showed that 2 cycles of 3.5% DSS for 4 days and 4 days of pure drinking water between each cycle is sufficient to induce chronic phase of IBD in C57BL/6 mice. We have seen that the acute phase (day 4) was characterized by clinical symptoms (visible rectal bleeding, diarrhea, and weight loss), and chronic phase (day 12 and after that) was characterized by recovering body weight, few clinical symptoms, high inflammatory score, and histopathological changes.

We examined that exposure to 4-5% DSS (for 4 days) has often led to the death of mice; therefore lower concentration (3.5%) was used. Based on clinical and histopathological findings, our results were similar to other articles (15,21,29). However, we achieved very acceptable results in less time. Also, low doses of DSS (1-2 %) were tested in our study but did not achieve the satisfactory results. The mice at day 7 were entered in the acute phase, but did not have a good physical condition and

Figure 6. Consideration of histopathologic changes in the mice that received 2 cycles of DSS for 4 days and 4 days pure water between each cycle. a) Loss of crypts; b) Slightly changes in the surface epithelium; c) Reduction of goblet cells; d) Visible infiltration of inflammatory cells.
most of them died on day 10.

Wirtz et al. recommended that three to five cycles with one week interval is needed for chemically induced mouse models of intestinal inflammation, while noticing that at the end of the second cycle, the weight has been 20% decreased and continuing other cycles may lead to the death of animals.

The main difference between induced DSS colitis procedures model in this study and other investigations are confounding factors in the experimental setup, such as environmental conditions (intestinal microbiota, pathogen infection, food composition, stress factors, light), mouse house origin, and genetic backgrounds (30).

In summary, the acute and chronic model of colitis in C57BL/6 mice may be useful in the study of pathological inflammatory changes that were observed in ulcerative colitis. Also, we suggest that the chronic model is a useful and powerful tool that can be used to validate future therapeutic strategies and candidate treatments for IBD. Inducing experimental IBD model by chemical materials, mostly DSS, should be considered according to the environmental conditions and microbial flora differences.

Acknowledgment

The study was financially supported by Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. The authors would like to express special thanks to Dr. Martina Perše from Institute of Pathology, Medical Faculty, University of Ljubljana, Zaloška, Ljubljana, Slovenia for her valuable advice and suggestions on the study. This study has been extracted from PhD thesis of Niloofar Taghipour (Registration No: 750).

References

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-17.
2. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-94.
3. Ashwin N. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol 2013; 9: 367-74.
4. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008; 14: 354-77.
5. Burger D, Travis S. Conventional management of inflammatory bowel disease. Gastroenterology 2011; 140: 1827-37.
6. Bosani M, Ardizzone S, Bianchi Porro G. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 2009; 3: 77-97.
7. Elliott DE, Weinstock JV. Where are we on worms? Curr Opin Gastroenterol 2012; 28: 551-56.
8. Elliott DE, Weinstock JV. Helminth-host immunological interactions: prevention and control of immune-mediated diseases. Ann N Y Acad Sci 2012; 1247: 83-96.
9. Weinstock JV, Elliott DE. Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis 2009; 15: 128-33.
10. Kabeerdoss J, Pugazhendhi S, Subramanian V, Binder HJ, Ramakrishna BS. Exposure to hookworms in patients with Crohn’s disease: a case-control study. Aliment Pharmacol Therapeut 2011; 34: 923-30.
11. Snapper SB, Rosen FS, Mizoguchi E, Cohen P, KhanW, Liu C-H, et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 1998; 9: 81-91.
12. Matsumoto S, Okabe Y, Setoyama H, Takayama K, Ohtsuka J, Funahashi H, et al. Inflammatory bowel disease-like enteritis caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998; 43: 71-78.
13. Jurjusa AR, Khourya NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004; 50: 81-92.
14. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol 2000; 19: 51-62.
15. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007; 2: 541-46.

16. Pinho RA, Silveira PC, Silva LA, Luiz Streck E, Dal-Pizzol F, et al. N-acetylcysteine and deferoxamine reduce pulmonary oxidative stress and inflammation in rats after coal dust exposure. Environ Res 2005; 99: 355-60.

17. Toth G, R FM, Lovas S. Stabilization of local structures by pi-CH and aromatic-backbone amide interactions involving prolyl and aromatic residues. Protein Eng 2001; 14: 543-47.

18. Axelsson LG, Landstrom E, Goldschmidt TJ, Gronberg A, Bylund-Fellenius AC. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(1)-cell depleted, athymic and NK-cell depleted SCID mice. Inflamm Res 1996; 45: 181-91.

19. Miyazawa F, Olijnyk OR, Tilley CJ, Tamaoki T. Interactions between dextran sulfate and Escherichia coli ribosomes. Biochim Biophys Acta 1967; 145: 96-104.

20. Nakamura T, Katori R, Watanabe T, Miyazawa K, Murai M, Oda J, et al. Quantitation of left-to-right shunt from a single earpiece dye-dilution curve. J Appl Physiol 1967; 22: 1156-60.

21. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694-702.

22. Melgar S, Karlsson A, MichaeÌÁsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005; 288: G1328-38.

23. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-49.

24. Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol 2014; 4: 104.

25. Obermeier F, Kojouharoff G, Hans W, Scholmerich J, Gross V, Falk W. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 1999; 116: 238-45.

26. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495-49.

27. Te Velde AA, Verstege MI, Hommes DW. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis 2006; 12: 995-99.

28. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514-21.

29. Kitajima S, Takuma S, Morimoto M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Anim 2000; 49: 9-15.

30. Nguyen TL, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? Dis Model Mech 2015; 8: 1-16.